| 5 star (1) | 100% |
Art (California ) on 06/28/2018: 
The following study discusses the use of synbiotics in pancreatitis and suggests that synbiotics (= prebiotic + probiotics). In this case, they used the common probiotics Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus and Bifidobacterium bifidum in a large dose (12 grams/day). As a prebiotic, they used Fructooligosaccharides (FOS).
Art
Here is a link to the abstract: https://www.ncbi.nlm.nih.gov/pubmed/29132740
Here is the abstract:
Clin Nutr ESPEN. 2017 Apr;18:9-15. doi: 10.1016/j.clnesp.2017.01.005. Epub 2017 Feb 21.
Effects of using symbiotics in the clinical nutritional evolution of patients with chronic pancreatitis: Study prospective, randomized, controlled, double blind.
Dos Santos PQ1, Guedes JC2, de Jesus RP3, Santos RRD3, Fiaconne RL4.
Abstract
Patients with chronic pancreatitis (CP) present malabsorption and changes in nutritional status. In this prospective, randomized, controlled, double-blinded, intervention study, developed at the Clinic of Pancreas, we aimed to assess whether the use of symbiotics changes the nutritional status, the biochemical data and the intestinal rate of these patients. The intervention consisted of administering 12 g/day of symbiotics composed of Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium bifidum and fructooligosaccharides to the intervention group and 12 g/day of medium absorption complex carbohydrate to the control group. The project was approved by the Ethics Committee of College of Technology and Science - FTC under the number process 0528-2008; reg. 498 e was registered under ClinicalTrials.gov. We evaluated 60 patients and the intervention lasted for 3 months, with monthly monitoring. A statistically significant reduction was observed in the results by day in relation to the initial frequency (x = 2.3) and the use of symbiotics in the second (x = 1.47) and third (x = 1.37) months (p = 0.001). In the control group, there was no significant change in this frequency (p = 0.157). The results showed an increase in the levels of hemoglobin (p < 0.001), hematocrit (p = 0.001), red blood cells (p < 0.001), total lymphocyte count (p < 0.002), serum magnesium (p < 0.001), albumin (0.001) and total serum cholesterol reduction (p < 0.001) with the use of symbiotics. The changes were not observed in the nutritional status of both groups.
CONCLUSION:
The use of symbiotics improved the clinical and laboratory profiles of the evaluated patients with CP, favoring the best clinical outcome, and may be a therapeutic option because of the low cost and therapeutic effectiveness in this population.
Copyright © 2017 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
